Improved Patient Outcomes and Financial Performance

Provided By:

Dohmen

May 18, 2017

Neither orphan drug manufacturers nor their patients with rare diseases are served well by the traditional multi-channel model of drug delivery and patient service. A new integrated model increases adherence and improves patient outcomes, which in turn leads to better financial performance for manufacturers.

Post a Comment

You must be logged in to post a Comment.

FEEDBACK